Antares Pharma (NASDAQ:ATRS) Earns Buy Rating from Raymond James

Antares Pharma (NASDAQ:ATRS)‘s stock had its “buy” rating reaffirmed by equities researchers at Raymond James in a research note issued on Thursday, AnalystRatings.com reports.

A number of other research analysts have also commented on the stock. Zacks Investment Research lowered shares of Antares Pharma from a “hold” rating to a “sell” rating in a research report on Monday, August 10th. HC Wainwright reaffirmed a “buy” rating on shares of Antares Pharma in a report on Monday, August 10th. BidaskClub raised Antares Pharma from a “strong sell” rating to a “sell” rating in a report on Friday, September 11th. LADENBURG THALM/SH SH restated a “buy” rating and issued a $7.00 target price on shares of Antares Pharma in a research note on Sunday, June 21st. Finally, Piper Sandler reiterated an “overweight” rating and set a $5.00 price target on shares of Antares Pharma in a research note on Sunday, June 21st. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $5.63.

NASDAQ:ATRS traded up $0.14 during mid-day trading on Thursday, hitting $2.84. 1,188,733 shares of the company’s stock traded hands, compared to its average volume of 1,295,676. The firm has a market capitalization of $448.45 million, a price-to-earnings ratio of 71.02 and a beta of 1.24. The firm has a 50 day moving average of $2.77 and a two-hundred day moving average of $2.72. The company has a current ratio of 2.90, a quick ratio of 2.41 and a debt-to-equity ratio of 0.71. Antares Pharma has a 12 month low of $1.60 and a 12 month high of $5.13.

Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter. The business had revenue of $32.38 million for the quarter, compared to the consensus estimate of $29.25 million. Antares Pharma had a net margin of 4.04% and a return on equity of 10.58%. As a group, equities research analysts expect that Antares Pharma will post 0.06 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in the company. Aperio Group LLC lifted its position in shares of Antares Pharma by 28.5% during the 1st quarter. Aperio Group LLC now owns 25,433 shares of the specialty pharmaceutical company’s stock worth $60,000 after buying an additional 5,646 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of Antares Pharma by 70.1% during the first quarter. Wells Fargo & Company MN now owns 304,328 shares of the specialty pharmaceutical company’s stock valued at $717,000 after acquiring an additional 125,440 shares during the period. AQR Capital Management LLC boosted its stake in shares of Antares Pharma by 780.3% in the 2nd quarter. AQR Capital Management LLC now owns 851,303 shares of the specialty pharmaceutical company’s stock valued at $2,341,000 after purchasing an additional 754,597 shares in the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of Antares Pharma by 1,615.5% in the 1st quarter. BNP Paribas Arbitrage SA now owns 325,096 shares of the specialty pharmaceutical company’s stock worth $767,000 after purchasing an additional 306,145 shares during the last quarter. Finally, Swiss National Bank increased its position in shares of Antares Pharma by 1.4% during the 1st quarter. Swiss National Bank now owns 300,700 shares of the specialty pharmaceutical company’s stock worth $710,000 after purchasing an additional 4,200 shares in the last quarter. Institutional investors own 42.96% of the company’s stock.

Antares Pharma Company Profile

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Read More: Understanding dividend yield and dividend payout ratio

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.